Congress Could Have Major Impact on Biotech Companies
10:48 am ET July 21, 2017 (PR Newswire) Print
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.
The rewritten package would add $70 billion to the $112 billion for states to use to help curb the growth of premiums and consumers' other out-of-pocket costs. It also includes $45 billion for states to combat the misuse of drugs like opioids. What isn't clear on the new health care repeal is how it will affect regenerative medicine and advances in biotechnology. Regenerative medicine is a life changing area of medicine that has the potential to fully heal damaged organs and tissues.
Regenerative medicine aims to improve the quality of life for patients suffering from life threatening diseases. Governments, scientists, universities, and private companies work with this powerful technology to create new body parts from a patient's own cells and tissues. While the United States is in limbo in terms of government health care reform, it is essential to track private biotechnology companies as they navigate through clinical trials and new drug implementation. Biotech companies furthering the regenerative medical field include: Endonovo Therapeutics (OTC: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), FibroGen, Inc. (NASDAQ: FGEN), OraSure Technologies, Inc. (NASDAQ: OSUR) and Capricor Therapeutics (NASDAQ: CAPR).
Endonovo Therapeutics (OTC: ENDV) ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They operate as an intellectual property licensing and commercialization company and a biomedical research and development company, allowing them to license and develop life-changing regenerative medical products across several platforms. Their Immunotronic technology uses non-invasive electromagnetic pulses to deliver electrical stimulation via inductive coupling to the nervous system and cells. At the end of June, ENDV released an open letter to shareholders providing updates on their pre-clinical study in Myocardial Infraction.
10:48 am ET July 21, 2017 (PR Newswire) Print
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.
The rewritten package would add $70 billion to the $112 billion for states to use to help curb the growth of premiums and consumers' other out-of-pocket costs. It also includes $45 billion for states to combat the misuse of drugs like opioids. What isn't clear on the new health care repeal is how it will affect regenerative medicine and advances in biotechnology. Regenerative medicine is a life changing area of medicine that has the potential to fully heal damaged organs and tissues.
Regenerative medicine aims to improve the quality of life for patients suffering from life threatening diseases. Governments, scientists, universities, and private companies work with this powerful technology to create new body parts from a patient's own cells and tissues. While the United States is in limbo in terms of government health care reform, it is essential to track private biotechnology companies as they navigate through clinical trials and new drug implementation. Biotech companies furthering the regenerative medical field include: Endonovo Therapeutics (OTC: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), FibroGen, Inc. (NASDAQ: FGEN), OraSure Technologies, Inc. (NASDAQ: OSUR) and Capricor Therapeutics (NASDAQ: CAPR).
Endonovo Therapeutics (OTC: ENDV) ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They operate as an intellectual property licensing and commercialization company and a biomedical research and development company, allowing them to license and develop life-changing regenerative medical products across several platforms. Their Immunotronic technology uses non-invasive electromagnetic pulses to deliver electrical stimulation via inductive coupling to the nervous system and cells. At the end of June, ENDV released an open letter to shareholders providing updates on their pre-clinical study in Myocardial Infraction.
